Details of the Drug

General Information of Drug (ID: DM4K7GQ)

Drug Name
Erythromycin
Synonyms
Abboticin; Abomacetin; Acneryne; Acnesol; Aknemycin; Aknin; AustriaS; Benzamycin; Derimer; Deripil; Dotycin; Dumotrycin; ERY; ERYC; Emgel; Emuvin; Emycin; Endoeritrin; Erecin; Erisone; Eritomicina; Eritrocina; Eritromicina; Ermycin; Eros; Eryacne; Eryacnen; Erycen; Erycette; Erycin; Erycinum; Eryderm; Erydermer; Erygel; Eryhexal; Erymax; Erymed; Erysafe; Erytab; Erythro; Erythroderm; Erythrogran; Erythroguent; Erythromid; Erythromycine; Erythromycinum; Erytop; Erytrociclin; Ilocaps; Iloticina; Ilotycin; Inderm; IndermRetcin; Latotryd; Lederpax; Mephamycin; Mercina; Oftamolets; Paediathrocin; Pantoderm; Pantodrin; Pantomicina; Pharyngocin; Primacine; Propiocine; Proterytrin; Retcin; Robimycin; Romycin; Sansac; Staticin; Stiemicyn; Stiemycin; Tiloryth; Tiprocin; Torlamicina; Wemid; Akne Cordes Losung; Aknederm Ery Gel; Benzamycin Pak; ERYTHROMYCIN STEARATE; Eryc Sprinkles; Erythromycin A; Erythromycin Lactate; Erythromycin Ointment; Erythromycin base; Erythromycin intravenous; Erythromycin sodium lauryl sulfate; Inderm Gel; Oftalmolosa Cusi Eritromicina; Skid Gel E; Theramycin Z; Udima Ery Gel; E0751; Eryc 125; Erythromast 36; Ak-Mycin; Akne-Mycin; Del-Mycin; E-Base; E-Glades; E-Mycin; E-Solve 2; ERYC (base); Emu-V; Emu-Ve; Erimycin-T; Eritromicina [INN-Spanish]; Ery-B; Ery-Diolan; Ery-Sol; Ery-Tab; Ery-maxin; Eryc (TN); Eryc-125; Eryc-250; Erygel (TN); Erythra-Derm; Erythro-Statin; Erythro-Teva; Erythromycin & VRC3375; Erythromycine [INN-French]; Erythromycinum [INN-Latin]; Ilosone (TN); Ilosone (estolate); Ilotycin T.S; Kesso-Mycin; N-Methylerythromycin A; PCE Dispertab (base); Pce (TN); R-P Mycin; Sans-acne; Staticin (TN); T-Stat; Taimoxin-F; A/T/S; Akne-mycin (TN); C-Solve-2; E-Base (base); E-Mycin (base); Ery-Tab (base); Erythromycin [INN:BAN:JAN]; Ilotycin T.S.; T-stat (TN); E-mycin, Erycin, Robimysin; Erythromycin (JP15/USP/INN); Erythromycin, compd. with monododecyl sulfate, sodium salt; Sulfuric acid, monododecyl ester, sodium salt, compd. with erythromycin; Adecane-2,10-dione (non-preferred name); Erythromycin A, T-Stat, Pantomicina, HSDB 3074, Erytab, DRG-0279; Ery
Indication
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [1], [2]
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 733.9
Topological Polar Surface Area (xlogp) 2.7
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 5
Hydrogen Bond Acceptor Count (hbondacc) 14
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 7.3 +/- 3.9 mgh/L [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 1.8 mcg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.2 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Clearance
The clearance of drug is 0.53 +/- 0.13 L/h/kg [5]
Elimination
Under 5% of the orally administered dose of erythromycin is found excreted in the urine [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 3.5 hours [7]
Metabolism
The drug is metabolized via the hepatic [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 90.87869 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.1% [9]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.95 L/kg [9]
Water Solubility
The ability of drug to dissolve in water is measured as 2.1 mg/mL [4]
Chemical Identifiers
Formula
C37H67NO13
IUPAC Name
(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione
Canonical SMILES
CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O
InChI
InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1
InChIKey
ULGZDMOVFRHVEP-RWJQBGPGSA-N
Cross-matching ID
PubChem CID
12560
ChEBI ID
CHEBI:42355
CAS Number
114-07-8
DrugBank ID
DB00199
TTD ID
D02YIZ
VARIDT ID
DR00050
INTEDE ID
DR0614
ACDINA ID
D00241

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial 50S ribosomal RNA (Bact 50S rRNA) TTUWYEA NOUNIPROTAC Binder [10], [11], [12]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporter 2 (SLC22A7) DT0OC1Q S22A7_HUMAN Substrate [13]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [14]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [15]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [16]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [17]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [18]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Substrate [19]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [20]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [21]
Cytochrome P450 1B1 (CYP1B1) DE9QHP6 CP1B1_HUMAN Substrate [19]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [22]
Docosahexaenoic acid omega-hydroxylase (CYP4F11) DEIZLTN CP4FB_HUMAN Substrate [23]
Beta-glucuronidase (uidA) DE7IQ34 A0A2A5L2J1_LACRH Substrate [24], [25]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Erythromycin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Ofloxacin. Bacterial infection [1A00-1C4Z] [123]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [124]
Dalfopristin DM4LTKV Major Decreased metabolism of Erythromycin caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [125]
Clarithromycin DM4M1SG Major Decreased metabolism of Erythromycin caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [126]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Erythromycin and Sparfloxacin. Bacterial infection [1A00-1C4Z] [123]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Gemifloxacin. Bacterial infection [1A00-1C4Z] [123]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Norfloxacin. Bacterial infection [1A00-1C4Z] [123]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Levofloxacin. Bacterial infection [1A00-1C4Z] [123]
Moxifloxacin DMU8V4S Major Increased risk of prolong QT interval by the combination of Erythromycin and Moxifloxacin. Bacterial infection [1A00-1C4Z] [127]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Lomefloxacin. Bacterial infection [1A00-1C4Z] [124]
Telithromycin DMZ4P3A Major Decreased metabolism of Erythromycin caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [126]
⏷ Show the Full List of 11 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Erythromycin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Erythromycin and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [128]
Methylergonovine DMBEX4O Major Decreased metabolism of Erythromycin caused by Methylergonovine mediated inhibition of CYP450 enzyme. Abortion [JA00] [129]
Clindamycin DM15HL8 Moderate Competitive binding of the 50S ribosomal subunit when Erythromycin and Clindamycin are combined. Acne vulgaris [ED80] [130]
Tretinoin DM49DUI Moderate Decreased metabolism of Erythromycin caused by Tretinoin mediated inhibition of CYP450 enzyme. Acne vulgaris [ED80] [131]
Repaglinide DM5SXUV Moderate Decreased metabolism of Erythromycin caused by Repaglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [132]
Pioglitazone DMKJ485 Moderate Decreased metabolism of Erythromycin caused by Pioglitazone mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [133]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of Erythromycin and Thioguanine. Acute myeloid leukaemia [2A60] [134]
Ivosidenib DM8S6T7 Major Increased metabolism of Erythromycin caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [135]
Midostaurin DMI6E0R Moderate Decreased metabolism of Erythromycin caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [136]
Idarubicin DMM0XGL Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Idarubicin. Acute myeloid leukaemia [2A60] [137]
Daunorubicin DMQUSBT Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Daunorubicin. Acute myeloid leukaemia [2A60] [137]
Arn-509 DMT81LZ Moderate Accelerated clearance of Erythromycin due to the transporter induction by Arn-509. Acute myeloid leukaemia [2A60] [138]
Gilteritinib DMWQ4MZ Moderate Decreased metabolism of Erythromycin caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [138]
Oliceridine DM6MDCF Major Decreased metabolism of Erythromycin caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [139]
Loratadine DMF3AN7 Minor Decreased metabolism of Erythromycin caused by Loratadine mediated inhibition of CYP450 enzyme. Allergic/hypersensitivity disorder [4A80-4A8Z] [140]
Tacrine DM51FY6 Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Tacrine. Alzheimer disease [8A20] [124]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Galantamine. Alzheimer disease [8A20] [124]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Rivastigmine. Alzheimer disease [8A20] [124]
Donepezil DMIYG7Z Minor Decreased metabolism of Erythromycin caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [141]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Erythromycin and Metronidazole. Amoebiasis [1A36] [128]
Ranolazine DM0C9IL Major Decreased metabolism of Erythromycin caused by Ranolazine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [142]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Erythromycin and Bepridil. Angina pectoris [BA40] [124]
Dronedarone DMA8FS5 Major Decreased metabolism of Erythromycin caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [128]
Nifedipine DMSVOZT Moderate Decreased metabolism of Erythromycin caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [143]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Erythromycin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [144]
Buspirone DMBS632 Moderate Decreased metabolism of Erythromycin caused by Buspirone mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [128]
Clorazepate DMC3JST Moderate Decreased metabolism of Erythromycin caused by Clorazepate mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [145]
Alprazolam DMC7XDN Moderate Decreased metabolism of Erythromycin caused by Alprazolam mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [146]
Hydroxyzine DMF8Y74 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [124]
Halazepam DMPFWO6 Moderate Decreased metabolism of Erythromycin caused by Halazepam mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [146]
Chlordiazepoxide DMTN5XI Moderate Decreased metabolism of Erythromycin caused by Chlordiazepoxide mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [146]
Clobazam - Lundbeck DMW1OQ0 Moderate Decreased metabolism of Erythromycin caused by Clobazam - Lundbeck mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [146]
Promazine DMZAL7W Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Promazine. Appearance/behaviour symptom [MB23] [124]
Cilostazol DMZMSCT Major Decreased metabolism of Erythromycin caused by Cilostazol mediated inhibition of CYP450 enzyme. Arterial occlusive disease [BD40] [138]
Voriconazole DMAOL2S Major Decreased metabolism of Erythromycin caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [126]
Posaconazole DMUL5EW Major Decreased metabolism of Erythromycin caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [126]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Levalbuterol. Asthma [CA23] [147]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Terbutaline. Asthma [CA23] [148]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Pirbuterol. Asthma [CA23] [148]
Isoetharine DMITSEH Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Isoetharine. Asthma [CA23] [148]
Budesonide DMJIBAW Moderate Decreased metabolism of Erythromycin caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [149]
Aminophylline DML2NIB Moderate Decreased metabolism of Erythromycin caused by Aminophylline mediated inhibition of CYP450 enzyme. Asthma [CA23] [150]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Salbutamol. Asthma [CA23] [147]
Roflumilast DMPGHY8 Moderate Decreased metabolism of Erythromycin caused by Roflumilast mediated inhibition of CYP450 enzyme. Asthma [CA23] [151]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Formoterol. Asthma [CA23] [148]
Pimecrolimus DMZLGRB Minor Decreased metabolism of Erythromycin caused by Pimecrolimus mediated inhibition of CYP450 enzyme. Atopic eczema [EA80] [152]
Atomoxetine DM5L6HI Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Atomoxetine. Attention deficit hyperactivity disorder [6A05] [124]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [138]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Desipramine. Attention deficit hyperactivity disorder [6A05] [124]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Retigabine. Behcet disease [4A62] [124]
Cariprazine DMJYDVK Moderate Decreased metabolism of Erythromycin caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [153]
Erdafitinib DMI782S Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [154]
Loperamide DMOJZQ9 Major Decreased clearance of Erythromycin due to the transporter inhibition by Loperamide. Bowel habit change [ME05] [155]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Eribulin. Breast cancer [2C60-2C6Y] [124]
Talazoparib DM1KS78 Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [138]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Erythromycin caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [156]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Erythromycin caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [157]
HKI-272 DM6QOVN Major Decreased metabolism of Erythromycin caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [158]
LY2835219 DM93VBZ Moderate Decreased metabolism of Erythromycin caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [159]
Esterified estrogens DM9KZDO Moderate Decreased metabolism of Erythromycin caused by Esterified estrogens mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [128]
Tucatinib DMBESUA Major Decreased metabolism of Erythromycin caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [126]
Palbociclib DMD7L94 Moderate Decreased metabolism of Erythromycin caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [138]
Quinestrol DMJ6H1Z Moderate Decreased metabolism of Erythromycin caused by Quinestrol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [128]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Tamoxifen. Breast cancer [2C60-2C6Y] [124]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Erythromycin caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [160]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Erythromycin and Toremifene. Breast cancer [2C60-2C6Y] [124]
Bosutinib DMTI8YE Major Decreased metabolism of Erythromycin caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [128]
Estradiol DMUNTE3 Moderate Decreased metabolism of Erythromycin caused by Estradiol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [128]
Grepafloxacin DMGLX0T Major Increased risk of prolong QT interval by the combination of Erythromycin and Grepafloxacin. Bronchitis [CA20] [123]
Sotalol DML60TN Major Increased risk of prolong QT interval by the combination of Erythromycin and Sotalol. Cardiac arrhythmia [BC9Z] [124]
Dofetilide DMPN1TW Major Increased risk of prolong QT interval by the combination of Erythromycin and Dofetilide. Cardiac arrhythmia [BC9Z] [124]
Atorvastatin DMF28YC Major Decreased metabolism of Erythromycin caused by Atorvastatin mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [161]
Macitentan DMP79A1 Major Decreased metabolism of Erythromycin caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [162]
PF-04449913 DMSB068 Moderate Decreased metabolism of Erythromycin caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [163]
Fluorometholone DM2HKC4 Moderate Decreased metabolism of Erythromycin caused by Fluorometholone mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [164]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [148]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [147]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Salmeterol. Chronic obstructive pulmonary disease [CA22] [148]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Indacaterol. Chronic obstructive pulmonary disease [CA22] [148]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [148]
Fidaxomicin DMFP6MV Minor Decreased clearance of Erythromycin due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [165]
Anisindione DM2C48U Major Decreased metabolism of Erythromycin caused by Anisindione mediated inhibition of CYP450 enzyme. Coagulation defect [3B10] [166]
Regorafenib DMHSY1I Moderate Decreased metabolism of Erythromycin caused by Regorafenib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [128]
Irinotecan DMP6SC2 Moderate Decreased metabolism of Erythromycin caused by Irinotecan mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [124]
Oxaliplatin DMQNWRD Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Oxaliplatin. Colorectal cancer [2B91] [124]
Intedanib DMSTA36 Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Intedanib. Colorectal cancer [2B91] [167]
Isoproterenol DMK7MEY Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Isoproterenol. Conduction disorder [BC63] [147]
Levonorgestrel DM1DP7T Moderate Decreased metabolism of Erythromycin caused by Levonorgestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [128]
Ulipristal DMBNI20 Minor Decreased metabolism of Erythromycin caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [138]
Etonogestrel DMKA8J4 Moderate Decreased metabolism of Erythromycin caused by Etonogestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [128]
Levobupivacaine DM783CH Moderate Decreased metabolism of Erythromycin caused by Levobupivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [138]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Halothane. Corneal disease [9A76-9A78] [124]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Propofol. Corneal disease [9A76-9A78] [168]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Sevoflurane. Corneal disease [9A76-9A78] [124]
Ropivacaine DMSPJG2 Minor Decreased metabolism of Erythromycin caused by Ropivacaine mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [169]
Alfentanil DMVO0UB Major Decreased metabolism of Erythromycin caused by Alfentanil mediated inhibition of CYP450 enzyme. Corneal disease [9A76-9A78] [170]
Oxtriphylline DMLHSE3 Moderate Decreased metabolism of Erythromycin caused by Oxtriphylline mediated inhibition of CYP450 enzyme. Cough [MD12] [150]
Methadone DMTW6IU Major Increased risk of prolong QT interval by the combination of Erythromycin and Methadone. Cough [MD12] [124]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Clofazimine. Crohn disease [DD70] [171]
Mycophenolic acid DMU65NK Moderate Altered absorption of Erythromycin due to GI flora changes caused by Mycophenolic acid. Crohn disease [DD70] [172]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Erythromycin and Mifepristone. Cushing syndrome [5A70] [124]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Erythromycin and Pasireotide. Cushing syndrome [5A70] [124]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Osilodrostat. Cushing syndrome [5A70] [138]
Ivacaftor DMZC1HS Major Decreased metabolism of Erythromycin caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [138]
Ethanol DMDRQZU Minor Altered absorption of Erythromycin due to GI dynamics variation caused by Ethanol. Cystitis [GC00] [173]
MK-8228 DMOB58Q Moderate Decreased metabolism of Erythromycin caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [174]
Rivaroxaban DMQMBZ1 Moderate Decreased metabolism of Erythromycin caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [175]
Aprepitant DM053KT Moderate Decreased metabolism of Erythromycin caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [176]
Sertraline DM0FB1J Moderate Decreased metabolism of Erythromycin caused by Sertraline mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [177]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Trimipramine. Depression [6A70-6A7Z] [124]
Imipramine DM2NUH3 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Imipramine. Depression [6A70-6A7Z] [124]
Fluoxetine DM3PD2C Moderate Decreased metabolism of Erythromycin caused by Fluoxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [177]
Nortriptyline DM4KDYJ Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Nortriptyline. Depression [6A70-6A7Z] [124]
Vilazodone DM4LECQ Moderate Decreased metabolism of Erythromycin caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [178]
Nefazodone DM4ZS8M Major Decreased metabolism of Erythromycin caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [126]
Paroxetine DM5PVQE Moderate Decreased metabolism of Erythromycin caused by Paroxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [177]
OPC-34712 DMHG57U Major Decreased metabolism of Erythromycin caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [179]
Trazodone DMK1GBJ Moderate Decreased metabolism of Erythromycin caused by Trazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [180]
Amitriptyline DMK7F9S Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Amitriptyline. Depression [6A70-6A7Z] [124]
Amoxapine DMKITQE Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Amoxapine. Depression [6A70-6A7Z] [124]
Mirtazapine DML53ZJ Moderate Decreased metabolism of Erythromycin caused by Mirtazapine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [181]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Maprotiline. Depression [6A70-6A7Z] [124]
Venlafaxine DMR6QH0 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Venlafaxine. Depression [6A70-6A7Z] [128]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Erythromycin caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [182]
[3H]estrone-3-sulphate DMGPF0N Moderate Decreased metabolism of Erythromycin caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [128]
Citalopram derivative 1 DMITX1G Major Increased risk of prolong QT interval by the combination of Erythromycin and Citalopram derivative 1. Discovery agent [N.A.] [124]
PMID28870136-Compound-48 DMPIM9L Moderate Decreased metabolism of Erythromycin caused by PMID28870136-Compound-48 mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [150]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [124]
Ospemifene DMC4GEI Moderate Decreased metabolism of Erythromycin caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [183]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Deutetrabenazine. Dystonic disorder [8A02] [184]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Ingrezza. Dystonic disorder [8A02] [185]
Zonisamide DM0DTF7 Moderate Decreased metabolism of Erythromycin caused by Zonisamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [186]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Erythromycin caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [187]
Mephenytoin DM5UGDK Moderate Increased metabolism of Erythromycin caused by Mephenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [188]
Cenobamate DMGOVHA Moderate Increased metabolism of Erythromycin caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [189]
Stiripentol DMMSDOY Moderate Decreased metabolism of Erythromycin caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [138]
Phenytoin DMNOKBV Moderate Increased metabolism of Erythromycin caused by Phenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [188]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Erythromycin caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [188]
Clonazepam DMTO13J Moderate Decreased metabolism of Erythromycin caused by Clonazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [146]
Ethotoin DMXWOCP Moderate Increased metabolism of Erythromycin caused by Ethotoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [188]
Cannabidiol DM0659E Minor Decreased metabolism of Erythromycin caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [138]
Bay 80-6946 DMLOS5R Moderate Decreased metabolism of Erythromycin caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [190]
Tazemetostat DMWP1BH Major Decreased metabolism of Erythromycin caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [191]
Solifenacin DMG592Q Major Decreased metabolism of Erythromycin caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [128]
Mirabegron DMS1GYT Minor Decreased metabolism of Erythromycin caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [192]
Tolterodine DMSHPW8 Moderate Decreased metabolism of Erythromycin caused by Tolterodine mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [193]
Darifenacin DMWXLYZ Moderate Decreased metabolism of Erythromycin caused by Darifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [194]
Itraconazole DMCR1MV Major Decreased metabolism of Erythromycin caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [126]
Ketoconazole DMPZI3Q Major Decreased metabolism of Erythromycin caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [126]
Cimetidine DMH61ZB Moderate Decreased metabolism of Erythromycin caused by Cimetidine mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [128]
Cisapride DMY7PED Major Decreased metabolism of Erythromycin caused by Cisapride mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [146]
Ripretinib DM958QB Moderate Decreased metabolism of Erythromycin caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [128]
Sunitinib DMCBJSR Moderate Decreased metabolism of Erythromycin caused by Sunitinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [128]
Avapritinib DMK2GZX Major Decreased metabolism of Erythromycin caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [138]
Colchicine DM2POTE Major Decreased metabolism of Erythromycin caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [195]
Lincomycin DMVTHER Moderate Competitive binding of the 50S ribosomal subunit when Erythromycin and Lincomycin are combined. Gram-positive bacterial infection [1B74-1F40] [130]
Ergotamine DMKR3C5 Major Decreased metabolism of Erythromycin caused by Ergotamine mediated inhibition of CYP450 enzyme. Headache [8A80-8A84] [196]
Eplerenone DMF0NQR Major Decreased metabolism of Erythromycin caused by Eplerenone mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [197]
Digoxin DMQCTIH Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Digoxin. Heart failure [BD10-BD1Z] [198]
Digitoxin DMWVIGP Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Digitoxin. Heart failure [BD10-BD1Z] [198]
Boceprevir DMBSHMF Major Decreased metabolism of Erythromycin caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [126]
Simeprevir DMLUA9D Major Decreased metabolism of Erythromycin caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [128]
Telaprevir DMMRV29 Major Decreased metabolism of Erythromycin caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [126]
Daclatasvir DMSFK9V Moderate Decreased metabolism of Erythromycin caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [128]
GS-5885 DMSL3DX Moderate Decreased clearance of Erythromycin due to the transporter inhibition by GS-5885. Hepatitis virus infection [1E50-1E51] [199]
Rifapentine DMCHV4I Moderate Increased metabolism of Erythromycin caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [200]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Erythromycin and Brentuximab vedotin. Hodgkin lymphoma [2B30] [201]
Indinavir DM0T3YH Major Decreased metabolism of Erythromycin caused by Indinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [126]
MK-1439 DM215WE Minor Decreased metabolism of Erythromycin caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [202]
Delavirdine DM3NF5G Major Decreased metabolism of Erythromycin caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [126]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Erythromycin caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [126]
Nevirapine DM6HX9B Moderate Increased metabolism of Erythromycin caused by Nevirapine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [128]
Cobicistat DM6L4H2 Major Decreased metabolism of Erythromycin caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [126]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Erythromycin and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [203]
Dolutegravir DMCZGRE Minor Decreased metabolism of Erythromycin caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [204]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Erythromycin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [205]
Etravirine DMGV8QU Moderate Decreased metabolism of Erythromycin caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [206]
Rilpivirine DMJ0QOW Moderate Decreased metabolism of Erythromycin caused by Rilpivirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [207]
Amprenavir DMLMXE0 Major Decreased metabolism of Erythromycin caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [126]
Darunavir DMN3GCH Moderate Decreased metabolism of Erythromycin caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [208]
Atazanavir DMSYRBX Moderate Decreased metabolism of Erythromycin caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [128]
Maraviroc DMTL94F Moderate Decreased metabolism of Erythromycin caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [209]
Ritonavir DMU764S Major Decreased metabolism of Erythromycin caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [126]
Simvastatin DM30SGU Major Decreased metabolism of Erythromycin caused by Simvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [210]
Fluvastatin DM4MDJY Major Decreased metabolism of Erythromycin caused by Fluvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [211]
Lovastatin DM9OZWQ Major Decreased metabolism of Erythromycin caused by Lovastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [210]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Erythromycin and Mipomersen. Hyper-lipoproteinaemia [5C80] [212]
Rosuvastatin DMMIQ7G Minor Altered absorption of Erythromycin due to GI dynamics variation caused by Rosuvastatin. Hyper-lipoproteinaemia [5C80] [213]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Erythromycin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [124]
BMS-201038 DMQTAGO Major Decreased metabolism of Erythromycin caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [128]
Cerivastatin DMXCM7H Major Decreased metabolism of Erythromycin caused by Cerivastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [161]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Erythromycin caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [214]
Paricalcitol DMYBV3G Moderate Decreased metabolism of Erythromycin caused by Paricalcitol mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [138]
Aliskiren DM1BV7W Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [124]
Levamlodipine DM92S6N Moderate Decreased metabolism of Erythromycin caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [124]
Isradipine DMA5XGH Moderate Decreased metabolism of Erythromycin caused by Isradipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [215]
Verapamil DMA7PEW Major Decreased metabolism of Erythromycin caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [126]
Diltiazem DMAI7ZV Major Decreased metabolism of Erythromycin caused by Diltiazem mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [126]
Amlodipine DMBDAZV Moderate Decreased metabolism of Erythromycin caused by Amlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [124]
Felodipine DMOSW35 Moderate Decreased metabolism of Erythromycin caused by Felodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [216]
Tolvaptan DMIWFRL Moderate Decreased metabolism of Erythromycin caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [217]
Fludrocortisone DMUDIR8 Moderate Decreased metabolism of Erythromycin caused by Fludrocortisone mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [215]
Retapamulin DM9JXB7 Minor Decreased metabolism of Erythromycin caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [218]
Rhucin DM3ADGP Major Decreased metabolism of Erythromycin caused by Rhucin mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [128]
Berotralstat DMWA2DZ Major Decreased clearance of Erythromycin due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [219]
Suvorexant DM0E6S3 Major Decreased metabolism of Erythromycin caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [220]
Ramelteon DM7IW9J Moderate Decreased metabolism of Erythromycin caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [221]
Eszopiclone DM8RZ9H Moderate Decreased metabolism of Erythromycin caused by Eszopiclone mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [222]
Flurazepam DMAL4G0 Moderate Decreased metabolism of Erythromycin caused by Flurazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [146]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Erythromycin caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [223]
ITI-007 DMUQ1DO Major Decreased metabolism of Erythromycin caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [224]
Zolpidem DMWOSKJ Moderate Decreased metabolism of Erythromycin caused by Zolpidem mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [225]
Quazepam DMY4D87 Moderate Decreased metabolism of Erythromycin caused by Quazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [146]
Estazolam DMZGXUM Moderate Decreased metabolism of Erythromycin caused by Estazolam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [146]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Polyethylene glycol. Irritable bowel syndrome [DD91] [138]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Phenolphthalein. Irritable bowel syndrome [DD91] [124]
Alosetron DML2A03 Moderate Decreased metabolism of Erythromycin caused by Alosetron mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [226]
Naloxegol DML0B41 Major Decreased metabolism of Erythromycin caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [138]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Erythromycin and Crizotinib. Lung cancer [2C25] [227]
Brigatinib DM7W94S Major Decreased metabolism of Erythromycin caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [128]
Ceritinib DMB920Z Major Decreased metabolism of Erythromycin caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [126]
Erlotinib DMCMBHA Moderate Decreased metabolism of Erythromycin caused by Erlotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [228]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Erythromycin caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [229]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Erythromycin and Osimertinib. Lung cancer [2C25] [230]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Erythromycin caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [231]
Capmatinib DMYCXKL Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [232]
Selpercatinib DMZR15V Major Decreased metabolism of Erythromycin caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [138]
Artemether DM48QOT Major Decreased metabolism of Erythromycin caused by Artemether mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [128]
Halofantrine DMOMK1V Major Decreased metabolism of Erythromycin caused by Halofantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [233]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Erythromycin and Chloroquine. Malaria [1F40-1F45] [234]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Erythromycin and Hydroxychloroquine. Malaria [1F40-1F45] [234]
Quinine DMSWYF5 Major Decreased metabolism of Erythromycin caused by Quinine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [235]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Primaquine. Malaria [1F40-1F45] [124]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [138]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Erythromycin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [236]
Idelalisib DM602WT Major Decreased metabolism of Erythromycin caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [126]
GDC-0199 DMH0QKA Major Decreased metabolism of Erythromycin caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [128]
IPI-145 DMWA24P Moderate Decreased metabolism of Erythromycin caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [237]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Erythromycin and Arsenic trioxide. Mature B-cell lymphoma [2A85] [238]
Acalabrutinib DM7GCVW Major Decreased metabolism of Erythromycin caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [239]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Erythromycin and Clofarabine. Mature B-cell lymphoma [2A85] [240]
Ibrutinib DMHZCPO Major Decreased metabolism of Erythromycin caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [241]
Vincristine DMINOX3 Major Decreased metabolism of Erythromycin caused by Vincristine mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [242]
Ponatinib DMYGJQO Moderate Decreased metabolism of Erythromycin caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [243]
Arry-162 DM1P6FR Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Arry-162. Melanoma [2C30] [128]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Erythromycin and Vemurafenib. Melanoma [2C30] [124]
LGX818 DMNQXV8 Major Decreased metabolism of Erythromycin caused by LGX818 mediated inhibition of CYP450 enzyme. Melanoma [2C30] [244]
Dabrafenib DMX6OE3 Moderate Decreased metabolism of Erythromycin caused by Dabrafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [128]
Estrone DM5T6US Moderate Decreased metabolism of Erythromycin caused by Estrone mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [128]
Dienestrol DMBSXI0 Moderate Decreased metabolism of Erythromycin caused by Dienestrol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [128]
Conjugated estrogens DMLT0E1 Moderate Decreased metabolism of Erythromycin caused by Conjugated estrogens mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [128]
Ethinyl estradiol DMODJ40 Moderate Decreased metabolism of Erythromycin caused by Ethinyl estradiol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [128]
Nitisinone DMVS9WQ Moderate Decreased metabolism of Erythromycin caused by Nitisinone mediated inhibition of CYP450 enzyme. Metabolism inborn error [5C50] [124]
Methysergide DM1EF73 Major Decreased metabolism of Erythromycin caused by Methysergide mediated inhibition of CYP450 enzyme. Migraine [8A80] [129]
Dihydroergotamine DM5IKUF Major Decreased metabolism of Erythromycin caused by Dihydroergotamine mediated inhibition of CYP450 enzyme. Migraine [8A80] [196]
Ubrogepant DM749I3 Moderate Decreased metabolism of Erythromycin caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [245]
Almogran DM7I64Z Moderate Decreased metabolism of Erythromycin caused by Almogran mediated inhibition of CYP450 enzyme. Migraine [8A80] [246]
Rimegepant DMHOAUG Moderate Decreased metabolism of Erythromycin caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [247]
Eletriptan DMW649X Major Decreased metabolism of Erythromycin caused by Eletriptan mediated inhibition of CYP450 enzyme. Migraine [8A80] [248]
Lasmiditan DMXLVDT Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Lasmiditan. Migraine [8A80] [249]
Exjade DMHPRWG Moderate Decreased metabolism of Erythromycin caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [250]
Flibanserin DM70DTN Major Decreased metabolism of Erythromycin caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [251]
Midazolam DMXOELT Moderate Decreased metabolism of Erythromycin caused by Midazolam mediated inhibition of CYP450 enzyme. Mood/affect symptom [MB24] [128]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Erythromycin and Panobinostat. Multiple myeloma [2A83] [252]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Thalidomide. Multiple myeloma [2A83] [128]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Erythromycin and Siponimod. Multiple sclerosis [8A40] [128]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Erythromycin and Fingolimod. Multiple sclerosis [8A40] [124]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Erythromycin and Ozanimod. Multiple sclerosis [8A40] [253]
Deflazacort DMV0RNS Major Decreased metabolism of Erythromycin caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [138]
Romidepsin DMT5GNL Moderate Decreased metabolism of Erythromycin caused by Romidepsin mediated inhibition of CYP450 enzyme. Mycosis fungoides [2B01] [254]
Fedratinib DM4ZBK6 Minor Decreased metabolism of Erythromycin caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [138]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Erythromycin and Nilotinib. Myeloproliferative neoplasm [2A20] [124]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Erythromycin caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [138]
Imatinib DM7RJXL Moderate Decreased metabolism of Erythromycin caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [255]
Dasatinib DMJV2EK Major Decreased metabolism of Erythromycin caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [128]
Modafinil DMYILBE Minor Decreased metabolism of Erythromycin caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [128]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Erythromycin and Droperidol. Nausea/vomiting [MD90] [124]
Prochlorperazine DM53SRA Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Prochlorperazine. Nausea/vomiting [MD90] [124]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Promethazine. Nausea/vomiting [MD90] [124]
Rolapitant DM8XP26 Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [256]
Palonosetron DMBHMOX Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Palonosetron. Nausea/vomiting [MD90] [124]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Granisetron. Nausea/vomiting [MD90] [124]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Erythromycin and Dolasetron. Nausea/vomiting [MD90] [124]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Ondansetron. Nausea/vomiting [MD90] [124]
Entrectinib DMMPTLH Major Decreased metabolism of Erythromycin caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [128]
Sibutramine DMFJTDI Minor Decreased metabolism of Erythromycin caused by Sibutramine mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [257]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Erythromycin and Levomethadyl Acetate. Opioid use disorder [6C43] [138]
S-297995 DM26IH8 Moderate Decreased clearance of Erythromycin due to the transporter inhibition by S-297995. Opioid use disorder [6C43] [138]
Valdecoxib DMAY7H4 Moderate Decreased metabolism of Erythromycin caused by Valdecoxib mediated inhibition of CYP450 enzyme. Osteoarthritis [FA00-FA05] [258]
Olaparib DM8QB1D Major Decreased metabolism of Erythromycin caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [128]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Rucaparib. Ovarian cancer [2C73] [124]
Dextropropoxyphene DM23HCX Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Dextropropoxyphene. Pain [MG30-MG3Z] [126]
Butorphanol DM5KYPJ Major Decreased metabolism of Erythromycin caused by Butorphanol mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [259]
Buprenorphine DMPRI8G Moderate Decreased metabolism of Erythromycin caused by Buprenorphine mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [260]
Hydrocodone DMQ2JO5 Major Decreased metabolism of Erythromycin caused by Hydrocodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [261]
Oxycodone DMXLKHV Major Decreased metabolism of Erythromycin caused by Oxycodone mediated inhibition of CYP450 enzyme. Pain [MG30-MG3Z] [128]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Triclabendazole. Parasitic worm infestation [1F90] [124]
Istradefylline DM20VSK Moderate Decreased metabolism of Erythromycin caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [262]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Pimavanserin. Parkinsonism [8A00] [263]
Bromocriptine DMVE3TK Moderate Decreased metabolism of Erythromycin caused by Bromocriptine mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [138]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Apomorphine. Parkinsonism [8A00] [124]
Abametapir DM2RX0I Moderate Decreased metabolism of Erythromycin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [264]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Famotidine. Peptic ulcer [DA61] [128]
Cabergoline DMQ4HIN Major Decreased metabolism of Erythromycin caused by Cabergoline mediated inhibition of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [196]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Erythromycin and Macimorelin. Pituitary gland disorder [5A60-5A61] [265]
Prednisone DM2HG4X Moderate Decreased metabolism of Erythromycin caused by Prednisone mediated inhibition of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [215]
Betamethasone DMAHJEF Moderate Decreased metabolism of Erythromycin caused by Betamethasone mediated inhibition of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [215]
Hydrocortisone DMGEMB7 Moderate Decreased metabolism of Erythromycin caused by Hydrocortisone mediated inhibition of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [215]
Ergonovine DM0VEC1 Major Decreased metabolism of Erythromycin caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [129]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Erythromycin caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [266]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Ritodrine. Preterm labour/delivery [JB00] [148]
Progesterone DMUY35B Moderate Decreased metabolism of Erythromycin caused by Progesterone mediated inhibition of CYP450 enzyme. Preterm labour/delivery [JB00] [128]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Degarelix. Prostate cancer [2C82] [138]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Erythromycin and ABIRATERONE. Prostate cancer [2C82] [138]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Nilutamide. Prostate cancer [2C82] [138]
Enzalutamide DMGL19D Moderate Accelerated clearance of Erythromycin due to the transporter induction by Enzalutamide. Prostate cancer [2C82] [267]
Flutamide DMK0O7U Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Flutamide. Prostate cancer [2C82] [138]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Erythromycin and Relugolix. Prostate cancer [2C82] [268]
Darolutamide DMV7YFT Minor Decreased metabolism of Erythromycin caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [269]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Bicalutamide. Prostate cancer [2C82] [138]
Tamsulosin DM5QF9V Moderate Decreased metabolism of Erythromycin caused by Tamsulosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [270]
Silodosin DMJSBT6 Moderate Decreased metabolism of Erythromycin caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [271]
Dutasteride DMQ4TJK Moderate Decreased metabolism of Erythromycin caused by Dutasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [272]
Alfuzosin DMZVMKF Major Decreased metabolism of Erythromycin caused by Alfuzosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [128]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Levomepromazine. Psychotic disorder [6A20-6A25] [124]
Fluphenazine DMIT8LX Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Fluphenazine. Psychotic disorder [6A20-6A25] [124]
Triflupromazine DMKFQJP Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Triflupromazine. Psychotic disorder [6A20-6A25] [124]
Ambrisentan DMD1QXW Minor Decreased metabolism of Erythromycin caused by Ambrisentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [273]
Bosentan DMIOGBU Moderate Decreased metabolism of Erythromycin caused by Bosentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [274]
Riociguat DMXBLMP Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Riociguat. Pulmonary hypertension [BB01] [128]
Everolimus DM8X2EH Major Decreased metabolism of Erythromycin caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [275]
Temsirolimus DMS104F Moderate Decreased metabolism of Erythromycin caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [276]
Sorafenib DMS8IFC Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Sorafenib. Renal cell carcinoma [2C90] [124]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Erythromycin and Gatifloxacin. Respiratory infection [CA07-CA4Z] [127]
Upadacitinib DM32B5U Moderate Decreased metabolism of Erythromycin caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [277]
Tofacitinib DMBS370 Moderate Decreased metabolism of Erythromycin caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [128]
Dexamethasone DMMWZET Moderate Decreased metabolism of Erythromycin caused by Dexamethasone mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [215]
Quetiapine DM1N62C Major Decreased metabolism of Erythromycin caused by Quetiapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [278]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Erythromycin and Mesoridazine. Schizophrenia [6A20] [124]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Erythromycin and Thioridazine. Schizophrenia [6A20] [124]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Erythromycin caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [279]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Erythromycin and Iloperidone. Schizophrenia [6A20] [124]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Paliperidone. Schizophrenia [6A20] [124]
Haloperidol DM96SE0 Major Increased risk of prolong QT interval by the combination of Erythromycin and Haloperidol. Schizophrenia [6A20] [124]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Perphenazine. Schizophrenia [6A20] [124]
Chlorpromazine DMBGZI3 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Chlorpromazine. Schizophrenia [6A20] [124]
Clozapine DMFC71L Moderate Decreased metabolism of Erythromycin caused by Clozapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [280]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Trifluoperazine. Schizophrenia [6A20] [124]
Ziprasidone DMM58JY Major Increased risk of prolong QT interval by the combination of Erythromycin and Ziprasidone. Schizophrenia [6A20] [124]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Risperidone. Schizophrenia [6A20] [124]
Olanzapine DMPFN6Y Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Olanzapine. Schizophrenia [6A20] [128]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Erythromycin and Amisulpride. Schizophrenia [6A20] [128]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Asenapine. Schizophrenia [6A20] [124]
Pimozide DMW83TP Major Decreased metabolism of Erythromycin caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [146]
Fentanyl DM8WAHT Major Decreased metabolism of Erythromycin caused by Fentanyl mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [128]
Avanafil DM75CXN Major Decreased metabolism of Erythromycin caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [281]
Tadalafil DMJZHT1 Moderate Decreased metabolism of Erythromycin caused by Tadalafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [128]
Vardenafil DMTBGW8 Major Increased risk of prolong QT interval by the combination of Erythromycin and Vardenafil. Sexual dysfunction [HA00-HA01] [128]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Erythromycin caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [282]
LDE225 DMM9F25 Major Decreased metabolism of Erythromycin caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [283]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Erythromycin caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [138]
Gefitinib DM15F0X Moderate Decreased metabolism of Erythromycin caused by Gefitinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [228]
Larotrectinib DM26CQR Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [128]
Vinblastine DM5TVS3 Major Decreased metabolism of Erythromycin caused by Vinblastine mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [242]
Docetaxel DMDI269 Major Decreased clearance of Erythromycin due to the transporter inhibition by Docetaxel. Solid tumour/cancer [2A00-2F9Z] [284]
Trabectedin DMG3Y89 Moderate Decreased metabolism of Erythromycin caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [138]
Armodafinil DMGB035 Minor Decreased metabolism of Erythromycin caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [128]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Erythromycin and LEE011. Solid tumour/cancer [2A00-2F9Z] [124]
Epirubicin DMPDW6T Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Epirubicin. Solid tumour/cancer [2A00-2F9Z] [124]
Prednisolone DMQ8FR2 Moderate Decreased metabolism of Erythromycin caused by Prednisolone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [215]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Erythromycin and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [285]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [138]
Norethindrone DMTY169 Moderate Decreased metabolism of Erythromycin caused by Norethindrone mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [128]
Taxol DMUOT9V Moderate Decreased metabolism of Erythromycin caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [286]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [124]
Vinorelbine DMVXFYE Major Decreased clearance of Erythromycin due to the transporter inhibition by Vinorelbine. Solid tumour/cancer [2A00-2F9Z] [242]
Pitolisant DM8RFNJ Moderate Increased metabolism of Erythromycin caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [138]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [124]
Ivermectin DMDBX5F Moderate Decreased metabolism of Erythromycin caused by Ivermectin mediated inhibition of CYP450 enzyme. Strongyloidiasis [1F6B] [138]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Erythromycin and Naltrexone. Substance abuse [6C40] [287]
Warfarin DMJYCVW Major Decreased metabolism of Erythromycin caused by Warfarin mediated inhibition of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [166]
Ibutilide DMKXY2R Major Increased risk of prolong QT interval by the combination of Erythromycin and Ibutilide. Supraventricular tachyarrhythmia [BC81] [288]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Erythromycin and Adenosine. Supraventricular tachyarrhythmia [BC81] [124]
Zithromax DMN4H2O Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Zithromax. Syphilis [1A61-1A6Z] [124]
Pomalidomide DMTGBAX Moderate Decreased metabolism of Erythromycin caused by Pomalidomide mediated inhibition of CYP450 enzyme. Systemic sclerosis [4A42] [128]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Erythromycin caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [289]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Erythromycin due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [290]
Anagrelide DMSQ8MD Major Increased risk of prolong QT interval by the combination of Erythromycin and Anagrelide. Thrombocytosis [3B63] [124]
Apixaban DM89JLN Moderate Decreased metabolism of Erythromycin caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [138]
Brilinta DMBR01X Moderate Decreased metabolism of Erythromycin caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [138]
Dicumarol DMFQCB1 Major Decreased metabolism of Erythromycin caused by Dicumarol mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [138]
Clopidogrel DMOL54H Moderate Decreased metabolism of Erythromycin caused by Clopidogrel mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [291]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Lenvatinib. Thyroid cancer [2D10] [124]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Erythromycin and Cabozantinib. Thyroid cancer [2D10] [138]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Erythromycin and Papaverine. Tonus and reflex abnormality [MB47] [292]
Tizanidine DMR2IQ4 Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Tizanidine. Tonus and reflex abnormality [MB47] [124]
Trimetrexate DMDEA85 Minor Decreased metabolism of Erythromycin caused by Trimetrexate mediated inhibition of CYP450 enzyme. Toxoplasmosis [1F57] [293]
Sirolimus DMGW1ID Major Decreased clearance of Erythromycin due to the transporter inhibition by Sirolimus. Transplant rejection [NE84] [128]
Mycophenolate mofetil DMPQAGE Moderate Altered absorption of Erythromycin due to GI flora changes caused by Mycophenolate mofetil. Transplant rejection [NE84] [172]
Tacrolimus DMZ7XNQ Major Decreased clearance of Erythromycin due to the transporter inhibition by Tacrolimus. Transplant rejection [NE84] [294]
Saxagliptin DMGXENV Moderate Decreased metabolism of Erythromycin caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [138]
Diethylstilbestrol DMN3UXQ Moderate Decreased metabolism of Erythromycin caused by Diethylstilbestrol mediated inhibition of CYP450 enzyme. Vaginitis [GA02] [128]
Fexofenadine DM17ONX Minor Decreased clearance of Erythromycin due to the transporter inhibition by Fexofenadine. Vasomotor/allergic rhinitis [CA08] [295]
Astemizole DM2HN6Q Major Decreased metabolism of Erythromycin caused by Astemizole mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [140]
Desloratadine DM56YN7 Minor Decreased metabolism of Erythromycin caused by Desloratadine mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [296]
Triamcinolone DM98IXF Moderate Decreased metabolism of Erythromycin caused by Triamcinolone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [215]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [126]
Fluticasone DMGCSVF Minor Decreased metabolism of Erythromycin caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [124]
Disopyramide DM5SYZP Major Increased risk of prolong QT interval by the combination of Erythromycin and Disopyramide. Ventricular tachyarrhythmia [BC71] [128]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Erythromycin and Procainamide. Ventricular tachyarrhythmia [BC71] [124]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Propafenone. Ventricular tachyarrhythmia [BC71] [124]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Erythromycin and Flecainide. Ventricular tachyarrhythmia [BC71] [124]
Amiodarone DMUTEX3 Major Decreased metabolism of Erythromycin caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [297]
⏷ Show the Full List of 413 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 30 E00456 3000709 Colorant
FD&C blue no. 1 E00263 19700 Colorant
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Quinoline yellow WS E00309 24671 Colorant
Sodium citrate anhydrous E00102 6224 Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Vanillin E00049 1183 Flavoring agent
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carboxymethylcellulose sodium E00621 Not Available Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium E00625 Not Available Disintegrant
Citric acid monohydrate E00271 22230 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Crospovidone E00626 Not Available Disintegrant
FD&C red no. 3 E00629 Not Available Colorant
Hypromellose E00634 Not Available Coating agent
Lithol rubin BCA E00607 135423095 Colorant
Magnesium aluminum silicate E00462 3084116 Adsorbent; Binding agent; Disintegrant; Suspending agent; Viscosity-controlling agent
Magnesium hydroxide E00374 73981 Adsorbent; Buffering agent
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Propylene glycol distearate E00395 110800 Emollient; Opacifying agent; Surfactant
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide E00234 14798 Alkalizing agent
Sorbic acid E00441 643460 Antimicrobial preservative
Sorbitan monooleate E00503 9920342 Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 31 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Erythromycin 250 mg tablet 250 mg Oral Tablet Oral
Erythromycin 500 mg tablet 500 mg Oral Tablet Oral
Erythromycin 250 mg tablet 250 mg Delayed Release Oral Tablet Oral
Erythromycin 500 mg tablet 500 mg Delayed Release Oral Tablet Oral
Erythromycin 333 mg tablet 333 mg Delayed Release Oral Tablet Oral
Erythromycin 400 mg tablet 400 mg Oral Tablet Oral
Erythromycin 250 mg capsule 250 mg Delayed Release Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1456).
2 How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
3 FDA Approved Drug Products: Ery-Ped (erythromycin ethylsuccinate) granules for oral suspension
4 BDDCS applied to over 900 drugs
5 Stanczyk FZ, Roy S: Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids. Contraception. 1990 Jul;42(1):67-96.
6 MedSafe NZ: ERA (erythromycin stearate) oral filmtabs
7 Erythromycin, clarithromycin, and azithromycin: are the differences real? Clin Ther. 1996 Jan-Feb;18(1):56-72; discussion 55.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10 A synthetic alanyl-initiator tRNA with initiator tRNA properties as determined by fluorescence measurements: comparison to a synthetic alanyl-elongator tRNA. Nucleic Acids Res. 1991 Oct 25;19(20):5749-54.
11 Inhibition of 50S ribosomal subunit assembly in Haemophilus influenzae cells by azithromycin and erythromycin. Curr Microbiol. 2002 Jun;44(6):418-24.
12 Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21.
13 Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22.
14 Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther. 2011 May;89(5):693-701.
15 ABCG2: a perspective. Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13.
16 Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
17 Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids. Pharm Res. 2009 May;26(5):1270-82.
18 Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol. 2003 Jan;55(1):86-93.
19 Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
20 Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab Dispos. 1998 Nov;26(11):1053-7.
21 Differential regulation of CYP3A4 and CYP3A5 and its implication in drug discovery. Curr Drug Metab. 2017;18(12):1095-1105.
22 Helices F-G are important for the substrate specificities of CYP3A7. Drug Metab Dispos. 2007 Mar;35(3):484-92.
23 Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304.
24 Identification of Lactobacillus sakei genes induced during meat fermentation and their role in survival and growth. Appl Environ Microbiol. 2007 Apr;73(8):2522-31.
25 Degradation of various insecticides in cooked eggs during in vitro human digestion. Environ Pollut. 2018 Dec;243(Pt A):437-443.
26 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
27 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
28 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
29 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
30 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
31 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
32 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
33 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
34 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
35 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
36 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
37 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
38 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
39 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
40 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
41 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
42 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
43 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
44 Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
45 Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
46 Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
47 Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
48 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
49 A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
50 Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
51 Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
52 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
53 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
54 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
55 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
56 Drug Interactions Flockhart Table
57 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
58 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
59 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
60 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
61 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
62 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
63 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
64 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
65 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
66 Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999 Aug;20(8):1607-13.
67 Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. Clin Ther. 2008 Jul;30(7):1283-9.
68 Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
69 Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos. 1997 May;25(5):617-22.
70 Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
71 Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther. 2001 Feb;296(2):537-41.
72 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
73 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
74 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
75 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
76 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
77 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
78 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
79 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
80 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
81 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
82 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
83 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
84 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
85 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
86 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
87 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
88 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
89 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
90 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
91 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
92 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
93 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
94 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
95 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
96 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
97 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
98 Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158.
99 Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
100 Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
101 Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
102 Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82.
103 Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol. 2008 Apr;73(4):1151-8.
104 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
105 Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter. Drug Metab Pharmacokinet. 2017 Feb;32(1):116-119.
106 Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.
107 LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
108 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
109 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
110 Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
111 Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
112 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
113 FDA Drug Development and Drug Interactions
114 Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004 Oct;311(1):139-46.
115 An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae. Curr Microbiol. 2004 Oct;49(4):239-47.
116 Review of macrolides and ketolides: focus on respiratory tract infections. Drugs. 2001;61(4):443-98.
117 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
118 Depression of colony formation by human thymus-derived lymphocytes with rifampin and other antimicrobial agents. J Infect Dis. 1981 Jun;143(6):832-5.
119 Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. Antimicrob Agents Chemother. 2007 Sep;51(9):3385-7.
120 The streptogramin antibiotics: update on their mechanism of action. Expert Opin Investig Drugs. 1998 Apr;7(4):591-9.
121 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
122 The protein synthesis inhibitors, oxazolidinones and chloramphenicol, cause extensive translational inaccuracy in vivo. J Mol Biol. 2002 Sep 13;322(2):273-9.
123 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
124 Canadian Pharmacists Association.
125 Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77. [PMID: 11103749]
126 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
127 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
128 Cerner Multum, Inc. "Australian Product Information.".
129 Matthews NT, Havill JH "Ergotism with therapeutic doses of ergotamine tartrate." N Z Med J 89 (1979): 476-7. [PMID: 314074]
130 Hardman JG, Gilman AG, Limbird LE eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed." New York, NY: McGraw-Hill (1995):.
131 Adamson PC "Pharmacokinetics of all-trans-retinoic acid: clinical implications in acute promyelocytic leukemia." Semin Hematol 31 (1994): 14-7. [PMID: 7831580]
132 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
133 Product Information. Actos (pioglitazone) Takeda Pharmaceuticals America, Lincolnshire, IL.
134 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
135 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
136 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
137 Multum Information Services, Inc. Expert Review Panel.
138 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
139 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
140 Ament PW, Paterson A "Drug interactions with the nonsedating antihistamines." Am Fam Physician 56 (1997): 223. [PMID: 9225677]
141 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
142 Product Information. Ranexa (ranolazine). Calmoseptine Inc, Huntington Beach, CA.
143 Geronimo-Pardo M, Cuartero-Del-Pozo AB, Jimenez-Vizuete JM, Cortinas-Saez M, Peyro-Garcia R "Clarithromycin-nifedipine interaction as possible cause of vasodilatory shock." Ann Pharmacother 39 (2005): 538-42. [PMID: 15703161]
144 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
145 Mattila MJ, Idanpaanheikkila JJ, Tornwall M, Vanakoski J "Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance." Pharmacol Toxicol 73 (1993): 180-5. [PMID: 8265524]
146 Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17. [PMID: 8547740]
147 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
148 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
149 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
150 Amsden GW "Erythromycin, clarithromycin, and azithromycin: are the differences real?" Clin Ther 18 (1996): 56-72. [PMID: 8851453]
151 Lahu G, Huennemeyer A, Herzog R, et al. "Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide." Int J Clin Pharmacol Ther 47 (2009): 236-45. [PMID: 19356389]
152 Product Information. Elidel (pimecrolimus topical). Novartis Pharmaceuticals, East Hanover, NJ.
153 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
154 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
155 Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
156 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
157 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
158 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
159 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
160 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
161 Amsden GW, Kuye O, Wei GC "A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers." J Clin Pharmacol 42 (2002): 444-9. [PMID: 11936570]
162 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
163 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
164 Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease." Clin Pharmacokinet 43 (2004): 803-21. [PMID: 15355126]
165 Product Information. Dificid (fidaxomicin). Optimer Pharmaceuticals, San Diego, CA.
166 Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E "The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy." Chest 126(3 Suppl) (2004): 204S-233S. [PMID: 15383473]
167 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
168 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
169 Ekstrom G, Gunnarsson UB "Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes." Drug Metab Dispos 24 (1996): 955-61. [PMID: 8886604]
170 Bartkowski RR, Goldberg ME, Larijani GE, Boerner T "Inhibition of alfentanil metabolism by erythromycin." Clin Pharmacol Ther 46 (1989): 99-102. [PMID: 2501060]
171 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
172 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
173 Morasso MI, Chavez J, Gai MN, Arancibia A "Influence of alcohol consumption on erythromycin ethylsuccinate kinetics." Int J Clin Pharmacol 28 (1990): 426-9. [PMID: 2258252]
174 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
175 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
176 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
177 Lee DO, Lee CD "Serotonin syndrome in a child associated with erythromycin and sertraline." Pharmacotherapy 19 (1999): 894-6. [PMID: 10417041]
178 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
179 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
180 Dattilo PB, Nordin C "Prolonged QT associated with an overdose of trazodone." J Clin Psychiatry 68 (2007): 1309-10. [PMID: 17854263]
181 Okubo M, Murayama N, Miura J, Chiba Y, Yamazaki H "Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients." Biochem Pharmacol 93 (2015): 104-9. [PMID: 25475885]
182 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
183 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
184 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
185 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
186 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
187 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
188 Bachmann K, Schwartz JI, Forney RB Jr, Jauregui L "Single dose phenytoin clearance during erythromycin treatment." Res Commun Chem Pathol Pharmacol 46 (1984): 207-17. [PMID: 6515115]
189 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
190 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
191 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
192 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
193 Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L "Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity." Br J Clin Pharmacol 48 (1999): 564-72. [PMID: 10583027]
194 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
195 Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
196 Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
197 Product Information. Inspra (eplerenone). Searle, Chicago, IL.
198 Hughes J, Crowe A. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics.?J Pharmacol Sci. 2010;113(4):315-324. [PMID: 20724802]
199 Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
200 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
201 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
202 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
203 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
204 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
205 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
206 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
207 Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
208 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
209 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
210 Ayanian JZ, Fuchs CS, Stone RM "Lovastatin and rhabdomyolysis." Ann Intern Med 109 (1988): 682-3. [PMID: 3421582]
211 Product Information. Lescol (fluvastatin). Novartis Pharmaceuticals, East Hanover, NJ.
212 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
213 Product Information. Crestor (rosuvastatin). AstraZeneca Pharma Inc, Mississauga, ON.
214 Product Information. Sensipar (cinacalcet). Amgen USA, Thousand Oaks, CA.
215 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
216 Bailey DG, Bend JR, Arnold JMO, Tran LT, Spence JD "Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice." Clin Pharmacol Ther 60 (1996): 25-33. [PMID: 8689808]
217 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
218 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
219 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
220 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
221 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
222 Alderman CP, Gebauer MG, Gilbert AL, Condon JT "Possible interaction of zopiclone and nefazodone." Ann Pharmacother 35 (2001): 1378-80. [PMID: 11724087]
223 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
224 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
225 Farkas D, Volak L, Harmatz J, von Moltke L, Court M, Greenblatt D "Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem." Clin Pharmacol Ther 85 (2009): 644-50. [PMID: 19242403]
226 Product Information. Lotronex (alosetron). Glaxo Wellcome, Research Triangle Park, NC.
227 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
228 Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239]
229 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
230 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
231 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
232 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
233 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
234 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
235 Mirghani RA, Ericsson O, Tybring G, Gustafsson LL, Bertilsson L "Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man." Eur J Clin Pharmacol 59 (2003): 23-8. [PMID: 12743670]
236 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
237 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
238 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
239 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
240 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
241 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
242 Antoniou T, Tseng AL "Interactions between antiretrovirals and antineoplastic drug therapy." Clin Pharmacokinet 44 (2005): 111-145. [PMID: 15656694]
243 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
244 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
245 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
246 Product Information. Axert (almotriptan) Pharmacia and Upjohn, Kalamazoo, MI.
247 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
248 Product Information. Relpax (eletriptan). Pfizer U.S. Pharmaceuticals, New York, NY.
249 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
250 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
251 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
252 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
253 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
254 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
255 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
256 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
257 Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ.
258 Product Information. Bextra (valdecoxib). Pharmacia Corporation, Peapack, NJ.
259 Product Information. Butorphanol Tartrate (butorphanol). Apotex Corporation, Weston, FL.
260 Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
261 Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes." Br J Clin Pharmacol 57 (2004): 287-97. [PMID: 14998425]
262 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
263 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
264 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
265 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
266 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
267 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
268 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
269 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
270 Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
271 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
272 Product Information. Duagen (dutasteride). GlaxoSmithKline Healthcare, Pittsburgh, PA.
273 Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
274 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
275 Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
276 Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
277 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
278 DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
279 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
280 Funderburg LG, Vertrees JE, True JE, Miller AL "Seizure following addition of erythromycin to clozapine treatment." Am J Psychiatry 151 (1994): 1840-1. [PMID: 7977898]
281 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
282 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
283 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
284 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
285 Product Information. Vandetanib (vandetanib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
286 Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
287 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
288 Gitler B, Berger LS, Buffa SD "Torsades de pointes induced by erythromycin." Chest 105 (1994): 368-72. [PMID: 8306730]
289 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
290 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
291 Clarke TA, Waskell LA "The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin." Drug Metab Dispos 31 (2003): 53-9. [PMID: 12485953]
292 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
293 Product Information. Neutrexin (trimetrexate). US Bioscience, West Conshohocken, PA.
294 Cakaloglu Y, Tredger JM, Devlin J, Williams R "Importance of cytochrome p-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients." Hepatology 20 (1994): 309-16. [PMID: 7519161]
295 Product Information. Allegra (fexofenadine). Hoechst Marion-Roussel Inc, Kansas City, MO.
296 Product Information. Clarinex (desloratadine). Schering Corporation, Kenilworth, NJ.
297 Nattel S, Ranger S, Talajic M, et al "Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism." Am J Med 89 (1990): 235-8. [PMID: 2382671]